We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The AttenueX IntraVesical System for the Treatment of Female Stress Urinary Incontinence

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00492596
Recruitment Status : Completed
First Posted : June 27, 2007
Last Update Posted : August 11, 2014
Information provided by (Responsible Party):
Solace Therapeutics, Inc.

Brief Summary:
Over 11 million women in the United States suffer from stress urinary incontinence (SUI), the involuntary leakage of urine during routine physical activities such as laughing, coughing, exercising, or sneezing. SUI affects women of all ages and can result in significant emotional distress. The purpose of this study is to evaluate a non-surgical, investigational treatment intended to reduce or eliminate urine leakage due to stress urinary incontinence.

Condition or disease Intervention/treatment Phase
Urinary Incontinence, Stress Device: AttenueX IntraVesical System Procedure: Sham Procedure Phase 3

Detailed Description:
A multicenter, prospective, randomized, single-blinded, two-arm longitudinal trial of the safety and effectiveness of the AttenueX Device in reducing incontinence. Subjects randomized to the control arm will have the AttenueX Device inserted at the end of the 3-month control period. For those subjects who are randomized to the treatment group, the AttenueX Device will be inserted into the bladder on Day 0, and replaced every 90 days by a new device for nine months. Subjects randomized into the treatment group will be followed for a minimum of 12 months after receiving the AttenueX Device, while subjects randomized into the control group will be followed for 3 months without the AttenueX Device and a minimum of 12 months after receiving the AttenueX Device.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 166 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: An Evaluation of the AttenueX IntraVesical System in the Management of Female Subjects With Stress Urinary Incontinence
Study Start Date : June 2006
Primary Completion Date : April 2011
Study Completion Date : June 2011

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: device
insertion of balloon system
Device: AttenueX IntraVesical System
Insertion of the Solace AttenueX Intravesical System on Day 0
Other Name: Solace Balloon
Sham Comparator: sham
cystoscopy with sham system
Device: AttenueX IntraVesical System
Insertion of the Solace AttenueX Intravesical System on Day 0
Other Name: Solace Balloon
Procedure: Sham Procedure
Cystoscopy with Simulated Insertion of AttenuEX Intravescial System

Primary Outcome Measures :
  1. Stamey Grade [ Time Frame: 6-months ]

Secondary Outcome Measures :
  1. Pad Weight [ Time Frame: 6-months ]
  2. VLPP [ Time Frame: 6-months ]
  3. I-QOL [ Time Frame: 6-months ]
  4. Incontinence Episode Frequency [ Time Frame: 6-months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Female subjects ≥ 18 years of age
  • Experienced stress urinary incontinence (SUI) for at least 12-months and failed prior non-surgical treatment
  • VLPP ≥ 60cm H20
  • Stamey Grade ≥ 1
  • Free of local skin infection, impassable urethral strictures, trauma or necrosis
  • Provide written informed consent

Exclusion Criteria:

  • Pregnant or planning pregnancy
  • 3 or more urinary tract infections within previous year
  • Intrinsic sphincter deficiency
  • Incontinence surgery within previous 6-months
  • Cystocele ≥ grade 3
  • Previous pelvic radiation therapy
  • Presence of urethral abnormalities
  • Recent urosepsis
  • History of interstitial or follicular cystitis
  • Uncontrolled diabetes
  • Biofeedback within previous 3 months
  • Morbid obesity
  • Use of anticoagulants other than aspirin

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00492596

United States, Arizona
Arizona Urologic Specialists
Tucson, Arizona, United States, 85712
United States, California
Kaiser Permanente Medical Center
Downey, California, United States, 90242
Tower Urology Institute for Incontinence
Los Angeles, California, United States, 90048
Saad Juma Inc.
San Diego, California, United States, 92024
Kaiser Permanente Medical Center
San Diego, California, United States, 92120
United States, Colorado
Genitourinary Surgical Consultants
Denver, Colorado, United States, 80220
United States, Florida
Oak Ridge Medical Plaza
Ft. Lauderdale, Florida, United States, 33334
United States, Georgia
Midtown Urology, P.C.
Atlanta, Georgia, United States, 30308
United States, New Jersey
Atlantic Health Systems
Morristown, New Jersey, United States, 07960
United States, New York
Northeast Urogynecology
Albany, New York, United States, 12205
United States, South Carolina
Medical University of Southern Carolina
Charleston, South Carolina, United States, 29425
United States, Texas
Vanguard Urologic Institute
Houston, Texas, United States, 77054
United States, Washington
Integrity Medical Research
Seattle, Washington, United States, 98133
Sponsors and Collaborators
Solace Therapeutics, Inc.

Responsible Party: Solace Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT00492596     History of Changes
Other Study ID Numbers: SOL2004-001
First Posted: June 27, 2007    Key Record Dates
Last Update Posted: August 11, 2014
Last Verified: August 2014

Additional relevant MeSH terms:
Urinary Incontinence
Urinary Incontinence, Stress
Urination Disorders
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms
Behavioral Symptoms
Elimination Disorders
Mental Disorders